PALO ALTO, Calif., Feb. 19 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced that its year-end conference call and webcast will be held on Thursday, February 26, 2009 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) following the release earlier that day of the company's financial results for the fourth quarter and year ended December 31, 2008.
The conference call will be accessible via Telik's website at http://www.telik.com or by telephone at 800-288-8974 or 612-332-0226. An archive of the conference call will be available on the Telik website or by telephone at 800-475-6701 or 320-365-3844, access code 985835. The archive will be available from approximately 6:30 p.m. Eastern time on February 26 through March 19, 2009.
Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer and inflammatory diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(R), which enables the rapid and efficient discovery of small molecule drug candidates.
TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.
|SOURCE Telik, Inc.|
Copyright©2009 PR Newswire.
All rights reserved